Zoomlogi’s Henry Ames says exception handling still hinges on experienced staff, and AI agents could gather and document details for their judgment calls.
News|Articles|October 16, 2026
BioPharma Supply Chains of the Future: What to Know About Localization
Author(s)Mary Blenn
Avantor’s Mary Blenn outlines five considerations for biopharma supply chain localization, from customer demand visibility to cost, consistency and redundancy.
Advertisement
Advertisement
It’s a common refrain heard by chief operating officers, supply chain leaders and manufacturing heads from country-level sales and marketing organizations — we can’t succeed without having a local footprint that can quickly adapt to demand on the ground.
Related to this article
At LogiPharma USA 2026, BMS’s Kevin Cook explains why CMO partnerships must move beyond transactions toward shared goals and KPIs.
Cencora's Matt Sample explains how AI compares forecasts with ordering patterns to flag pharma demand shifts early, with 10% forecasting gains.
At LogiPharma USA 2026, Swisslog's Garrett Freeman explains why validation, change management and stakeholder alignment now drive automation projects.
Zoomlogi's Henry Ames explains how AI agents are resolving supply chain exceptions, from unlinked IoT trackers to after-hours escalation calls.
As organized groups add impersonation and email fraud to hijackings and trailer thefts, every handoff between shipping partners has become a point of exposure.
Octapharma USA's Kerem Tokel explains how product value and supply risk should shape freight security, and why complacency remains a persistent gap.
At LogiPharma USA 2026, Cold Chain Technologies' TJ Rizzo explains how gaps in end-to-end cold chain expertise create risk for advanced therapies.
Advertisement
Advertisement